Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: raltegravir (Drug)
Phase: N/A
Status: Approved for marketing
Sponsored by: Merck Sharp & Dohme Corp. Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.
Summary
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1
infection in patients who have limited or no treatment options due to virological failure,
resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is
patient driven. Investigators are not proactively assigned. There is no target sample size
and duration of the study is indefinite. For information on how to enroll in the study, see
link below.
Clinical Details
Official title: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options
Study design: N/A
Eligibility
Minimum age: 16 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HIV positive patients who have limited or no treatment options and have documented
resistance
Exclusion Criteria:
- Patient has previously been on MK0518 therapy
Locations and Contacts
Additional Information
Last updated: October 31, 2014
|